Search Within

Paul Marks

Formats
  1. Journal Article (121)
  2. Meeting Abstract (47)
  3. Book Section (10)
  4. Book Whole (4)
  5. Conference Paper (4)
Groups
  1. Department of Medicine (18)
  2. Center for Hematologic Malignancies (15)
  3. Solid Tumor Oncology Division (14)
  4. Surgery (13)
  5. GSK Faculty (12)
  6. Genitourinary Oncology Service (12)

More Groups

People
  1. Richard Rifkind (113)
  2. Victoria Richon (77)
  3. Lang Ngo (27)
  4. Gisela Venta-Perez (20)
  5. William Kelly (16)
  6. Weisheng Xu (13)

More People

Years
  1. 2015 (2)
  2. 2014 (2)
  3. 2013 (3)
  4. 2012 (4)
  5. 2011 (3)
  6. 2010 (6)

More Years

Publications
  1. Proceedings of the National Academy of Sciences of the United States of America (35)
  2. Proceedings of the American Association for Cancer Research Annual Meeting (19)
  3. Cancer Research (15)
  4. Blood (9)
  5. Clinical Cancer Research (9)
  6. Anticancer Research (5)

More Publications

Publishers
  1. American Association for Cancer Research (48)
  2. National Academy of Sciences (35)
  3. American Society of Hematology (9)
  4. Nature Publishing Group (8)
  5. Elsevier Inc. (7)
  6. John Wiley & Sons (6)

More Publishers

Results (186)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Prospects: Histone deacetylase inhibitors
    Journal Article

    Dokmanovic, M.; Marks, P. A.
    Journal of Cellular Biochemistry (2005)

    Fulltext@MSK | Save
  • Induction of mitotic defect is a novel anti-tumor mechanism of histone deacetylase inhibitor suberoylanilide hydroxamic acid
    Meeting Abstract

    Xu, W.; Perez, G.; Gui, C.; Thapi, D.; Ngo, L.; Richon, V. M.; Rifkind, R. A.; Marks, P. A.
    Cancer Research (2004)

    Fulltext@MSK | Save
  • Histone deacetylase inhibitor activation of p21 involves changes in promoter associated proteins, including HDAC1
    Meeting Abstract

    Gui, C.; Ngo, L.; Xu, W.; Thapi, D.; Perez, G. V.; Richon, V. M.; Rifkind, R. A.; Marks, P. A.
    Cancer Research (2004)

    Fulltext@MSK | Save
  • The mechanism of the anti-tumor activity of the histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA)
    Journal Article

    Marks, P. A.
    Cell Cycle (2004)

    Fulltext@MSK | Save
  • Histone deacetylase inhibitors
    Journal Article

    Marks, P. A.; Richon, V. M.; Miller, T.; Kelly, W. K.
    Advances in Cancer Research (2004)

    Fulltext@MSK | Save
  • Histone deacetylase inhibitors: Development as cancer therapy
    Journal Article

    Marks, P. A.; Richon, V. M.; Kelly, W. K.; Chiao, J. H.; Miller, T.; Bock, G.; Goode, J.
    Novartis Foundation Symposia (2004)

    Fulltext@MSK | Save
  • Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications
    Journal Article

    Mitsiades, C. S.; Mitsiades, N. S.; McMullan, C. J.; Poulaki, V.; Shringarpure, R.; Hideshima, T.; Akiyama, M.; Chauhan, D.; Munshi, N.; Gu, X.; more...
    Proceedings of the National Academy of Sciences of the United States of America (2004)

    Fulltext@MSK | Save
  • Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1
    Journal Article

    Gui, C. Y.; Ngo, L.; Xu, W. S.; Richon, V. M.; Marks, P. A.
    Proceedings of the National Academy of Sciences of the United States of America (2004)

    Fulltext@MSK | Save
  • Histone deacetylase inhibitors: Assays to assess effectiveness in vitro and in vivo
    Journal Article

    Richon, V. M.; Zhou, X.; Secrist, J. P.; Cordon-Cardo, C.; Kelly, W. K.; Drobnjak, M.; Marks, P. A.
    Methods in Enzymology (2004)

    Fulltext@MSK | Save
  • Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid
    Journal Article

    Reilly, C. M.; Mishra, N.; Miller, J. M.; Joshi, D.; Ruiz, P.; Richon, V. M.; Marks, P. A.; Gilkeson, G. S.
    Journal of Immunology (2004)

    Fulltext@MSK | Save